



**Inter Science Institute**

944 W Hyde Park Blvd, Inglewood, CA 90302  
Email: Requests@interscienceinstitute.com  
Phone: 800-255-2873 | 310-677-3322 | Fax: 310-677-2846  
LABORATORY DIRECTOR: James Lee, MD, PhD

Patient:	Test, test	Accession:	1192
Patient #:	1007	Birth:	9/6/1969
Client:	TEST, TEST	Age:	54 years
		Gender:	Female
		Collection Date:	6/20/2024 12:00 AM
		Received Date:	6/20/2024 4:43 PM
		External Order Number	123

Test Name	Result	Units	Flag	Reference Range/Cutoff
-----------	--------	-------	------	------------------------

**Octreotide/Sandostatin**

Specimen Type/Container Type: Plasma/Lavender

Octreotide/Sandostatin	less than 100*	pg/mL	L	
------------------------	----------------	-------	---	--

\*Result is below the limit of quantitation.

Notes:

Expected levels of Octreotide administered by pump:

60 mg/month: 10,000 pg/mL ±2,500 pg/mL

30 mg/month: 5,000 pg/mL ±2,500 pg/mL

Octreotide administered as Sandostatin LAR:

120 mg/month: 9,000 pg/mL ±2,000 pg/mL

60 mg/month: 5,000 pg/mL ± 2,000 pg/mL

30 mg/month: 2,500 pg/mL ±1,500 pg/mL

Octreotide administered by subcutaneous injection:

Measurement of plasma Octreotide is not recommended for individuals using multiple daily Octreotide injections due to the short ½ life of Octreotide in the plasma (approximately 90-120 minutes).

Disclaimer: The choice of a specific dose of Octreotide is at the discretion of the individual treating physician and should take into account the patient's individual clinical situation.

This test was developed and its performance characteristics determined by Inter Science Institute. Values obtained with different methods, laboratories, or kits cannot be used interchangeably with the results on this report. The results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.



**Inter Science Institute**

944 W Hyde Park Blvd, Inglewood, CA 90302  
Email: Requests@interscienceinstitute.com  
Phone: 800-255-2873 | 310-677-3322 | Fax: 310-677-2846  
LABORATORY DIRECTOR: James Lee, MD, PhD

Patient:	Test, test	Accession:	1192
Patient #:	1007	Birth:	9/6/1969
Client:	TEST, TEST	Age:	54 years
		Gender:	Female
		Collection Date:	6/20/2024 12:00 AM
		Received Date:	6/20/2024 4:43 PM
		External Order Number	123

Test Name	Result	Units	Flag	Reference Range/Cutoff
-----------	--------	-------	------	------------------------

**Octreotide/Sandostatin**

Specimen Type/Container Type: Plasma/Lavender

Octreotide/Sandostatin 3548 pg/mL

Notes:

Expected levels of Octreotide administered by pump:

60 mg/month: 10,000 pg/mL ±2,500 pg/mL

30 mg/month: 5,000 pg/mL ±2,500 pg/mL

Octreotide administered as Sandostatin LAR:

120 mg/month: 9,000 pg/mL ±2,000 pg/mL

60 mg/month: 5,000 pg/mL ± 2,000 pg/mL

30 mg/month: 2,500 pg/mL ±1,500 pg/mL

Octreotide administered by subcutaneous injection:

Measurement of plasma Octreotide is not recommended for individuals using multiple daily Octreotide injections due to the short ½ life of Octreotide in the plasma (approximately 90-120 minutes).

Disclaimer: The choice of a specific dose of Octreotide is at the discretion of the individual treating physician and should take into account the patient's individual clinical situation.

This test was developed and its performance characteristics determined by Inter Science Institute. Values obtained with different methods, laboratories, or kits cannot be used interchangeably with the results on this report. The results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.